Pancreatic Cancer Research

ResearcherUniversity of TorontoActive in the last 2 years

Julie I. Hallet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5108-1072; OpenAlex author ID A5008281650. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2019: 4 papers · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 11

  1. Mismatch Repair, Matched with Hope? Revisiting Survival in MSI-H Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-025-17832-6↗
  2. Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline. Co-author DOI 10.3390/curroncol30070482↗
  3. Evaluation of Adherence to Venous Thromboembolism Prophylaxis Guidelines Among US Adults After Pancreatic Cancer Surgery. Co-author DOI 10.1001/jamasurg.2022.2590↗
  4. Initial treatment is associated with improved survival and end-of-life outcomes for patients with pancreatic cancer: a cohort study. Co-author DOI 10.1186/s12885-022-10342-8↗
  5. Symptom Burden of Nonresected Pancreatic Adenocarcinoma: An Analysis of 10,753 Patient-Reported Outcome Assessments. Co-author DOI 10.1097/mpa.0000000000001629↗
  6. Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. Co-author DOI 10.6004/jnccn.2019.7361↗
  7. Impact of Geography on Care Delivery and Survival for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. Last author DOI 10.6004/jnccn.2020.7605↗
  8. Population-based study of the prevalence and management of self-reported high pain scores in patients with non-resected pancreatic adenocarcinoma. Last author DOI 10.1002/bjs.11330↗
  9. Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarci… Last author DOI 10.1002/bjs5.50115↗
  10. Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life: a population based analysis of 2,538 patients. Co-author DOI 10.1016/j.hpb.2019.04.016↗
  11. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. Last author DOI 10.1503/cmaj.190211↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Natalie G. Coburn · 8 shared papers, 2019–2022 · strength 0.88
  2. Alexandra W. Acher · 1 shared paper, 2025 · strength 0.54
  3. Michail N. Mavros · 3 shared papers, 2019–2020 · strength 0.32
  4. Ahmed Hammad · 3 shared papers, 2019–2020 · strength 0.29
  5. Ying Liu · 2 shared papers, 2019–2020 · strength 0.21
  6. Stephanie Tung · 2 shared papers, 2019–2020 · strength 0.20
  7. Khalid Hirmiz · 1 shared paper, 2023 · strength 0.19
  8. Aamer Mahmud · 1 shared paper, 2023 · strength 0.19
  9. Rachel Anne Goodwin · 1 shared paper, 2023 · strength 0.19
  10. James Biagi · 1 shared paper, 2023 · strength 0.19
  11. Sten D. Myrehaug · 2 shared papers, 2019 · strength 0.19
  12. Sepideh Gholami · 1 shared paper, 2022 · strength 0.17
  13. Lauren M. Perry · 1 shared paper, 2022 · strength 0.17
  14. Robert J. Canter · 1 shared paper, 2022 · strength 0.17
  15. Ryan P. Merkow · 1 shared paper, 2022 · strength 0.17
  16. Sarah B. Bateni · 1 shared paper, 2022 · strength 0.17
  17. Richard J. Bold · 1 shared paper, 2022 · strength 0.17
  18. Paul Damien James · 1 shared paper, 2022 · strength 0.16
  19. Peter Tanuseputro · 1 shared paper, 2022 · strength 0.16
  20. Rishad Khan · 1 shared paper, 2022 · strength 0.16
  21. Elliott Kenneth Yee · 1 shared paper, 2020 · strength 0.11
  22. Nicholas Latchana · 1 shared paper, 2019 · strength 0.09
  23. Daniel Jonathan Kagedan · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.